Unlock instant, AI-driven research and patent intelligence for your innovation.

Target molecules for the development of therapeutic products for cervical diseases

A technique for cervical squamous cell carcinoma and drug candidates, applied in the field of biomedicine

Active Publication Date: 2021-11-26
QINGDAO MEDINTELL BIOMEDICAL CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, gene therapy for cervical cancer is still in the exploratory stage, especially in my country, where clinical research reports are limited, and more research and exploration are needed to truly become a new clinical treatment method

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Target molecules for the development of therapeutic products for cervical diseases
  • Target molecules for the development of therapeutic products for cervical diseases
  • Target molecules for the development of therapeutic products for cervical diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0066] Example 1 Screening for Gene Markers Related to Cervical Squamous Cell Carcinoma

[0067] 1. Sample collection

[0068] 32 cases of cervical squamous cell carcinoma (CESC) tissues, 18 normal tissues (N), and 24 cases of cervical intraepithelial neoplasia (CIN) tissues were collected. All cases did not receive any immunosuppressant treatment, radiotherapy and chemotherapy before operation. All included All the subjects signed the informed consent before collecting the specimens. All the above specimens were obtained with the consent of the organizational ethics committee. Four samples were taken from each group for detection and analysis of gene expression profiles, screening of differentially expressed genes, and verification experiments were carried out in all case samples of each group.

[0069] 2. Preparation of RNA samples

[0070] Use QIAGEN tissue RNA extraction kit to extract total RNA in each group of tissues, please refer to the instruction manual for specif...

Embodiment 2

[0081] Example 2 QPCR sequencing to verify differential expression of FRMD4B gene

[0082] 1. Large-sample QPCR verification of differential expression of FRMD4B gene.

[0083] 2. RNA extraction

[0084] Use QIAGEN tissue RNA extraction kit to extract total RNA in each group of tissues, please refer to the instruction manual for specific steps.

[0085] 3. QPCR

[0086] 1) Reverse transcription reaction

[0087] Use FastQμant cDNA First Strand Synthesis Kit (Product No.: KR106) for lncRNA reverse transcription, first remove the genomic DNA reaction, add 5×gDNA Bμffer 2.0μl, total RNA 1μg, add RNase Free ddH 2 O to bring the total volume to 10 μl, and heat in a water bath at 42°C for 3 min.

[0088] 10× Fast RT Bμffer 2.0μl, RT Enzyme Mix 1.0μl, FQ-RT Primer Mix 2.0μl, RNase Free ddH 2 O 5.0 μl, after mixing, add to the above test tube and mix together a total of 20 μl, heat in a water bath at 42°C for 15min, then at 95°C for 3min.

[0089] 2) Primer design

[0090] QPCR a...

Embodiment 3

[0108] Example 3 Overexpression of FRMD4B gene

[0109] According to the FRMD4B gene sequence information in NCBI, specific primers were designed and amplified to obtain the corresponding genes. After the gene fragments were recovered by gel, they were connected with the expression vector pEGFP-C1 and transformed into DH5α competent cells. Positive clones were picked and subjected to PCR and After sequencing and identification, the pEGFP-C1-FRMD4B recombinant plasmid was obtained.

[0110] 1. Cell culture

[0111] Cervical squamous cell carcinoma cells (Hela) were cultured in RPIM-1640 medium containing 10% fetal bovine serum and 1% P / S at 37°C, 5% CO 2 When the cells grew to 80%-90%, they were routinely digested and passaged with 0.25% EDTA-containing trypsin.

[0112] 2. Transfection

[0113] The experiment was divided into 3 groups, namely the control group (Hela), the blank control group (transfected with pEGFP-C1), and the experimental group (transfected with pEGFP-C1-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses target molecules for the development of diagnosis and treatment products for cervical diseases. Through high-throughput sequencing technology combined with bioinformatics analysis, the present invention finds for the first time that the expression of FRMD4B is down-regulated in cervical intraepithelial neoplasia and cervical squamous cell carcinoma, and Further QPCR and cell experiments proved that FRMD4B is related to the occurrence and development of cervical squamous cell carcinoma, suggesting that FRMD4B can be used as a target molecule in the development of diagnostic products and therapeutic drugs for cervical squamous cell carcinoma.

Description

technical field [0001] The invention belongs to the field of biomedicine, and relates to target molecules used for developing diagnosis and treatment products for cervical diseases, and the specifically involved target molecules are FRMD4B. Background technique [0002] Cervical cancer refers to malignant tumors that occur at the junction of squamous epithelial cells of the cervicovaginal or transition zone and columnar epithelial cells of the endocervical canal. Worldwide, cervical cancer is the second most malignant tumor in women after breast cancer. Recent global data show that among women all over the world, the number of new cases per year is 460,000, and 260,000 patients die globally every year. For this disease, 80% of its cases occur in developing countries (Castellsague X. Natural history and epidemiology of HPV infection and cervical cancer [J]. Gyneco Oncol, 2008, 110(3): 4-7.), and its death toll accounts for The death toll of all malignant tumors is 18.4%, whi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6886G01N33/68G01N33/574
CPCC12Q1/6886C12Q2600/106C12Q2600/158G01N33/57407G01N33/57442G01N33/68
Inventor 杨承刚孙耀兰黄露宁
Owner QINGDAO MEDINTELL BIOMEDICAL CO LTD